Administration of Intravenous Immunoglobulins in Department of Neurology at Pauls Stradins Clinical University Hospital in 2021–2022

Activity: Talk or presentation types › Poster presentation

Description

Intravenous immunoglobulin (IvIg) is a type of immunomodulating therapy used in various disease treatment, including autoimmune, infectious, and inflammatory conditions. The aim of this study was to analyse indications, efficacy, and side effects of IvIg therapy in Department of Neurology at Pauls Stradiņš Clinical University Hospital (PSCUH) in a period 2021-2022.. Retrospective analysis of patients who received IvIg in Department of Neurology at PSCUH from 01.01.2021.-31.12.2022. We analysed patient files and daily recordings, evaluating indications for IvIg treatment, clinical outcome, and experienced side-effects.. Our study included 37 patients - 17 men (45,9%) and 20 women (54%). The mean age of patient was 57±16 years. 29 patients (78%) received IvIg during acute hospitalization, 8 patients (21,6%) – during planned hospitalization. 10 patients (27%) received IvIg because of CNS disorders (autoimmune encephalitis (16,2%), myelitis (5,4%) , acute disseminated encephalomyelitis 1 (2,7%), autoimmune encephalomyelitis (2,7%)), 3 patients (8,1%) received IvIg because of combined CNS and PNS disease (tick borne virus induced meningoradiculoneuritis (5,4%), subacute myelopolyradiculoneuritis (2,7%)), but 24 patients (64,8%) received IvIg for PNS disease (Myasthenia gravis (16,2%), Lambert-Eaton myasthenic syndrome (2,7%), Guillain – Barre syndrome (18,9%), chronic inflammatory demyelinating polyneuropathy (2,7%), multifocal motor neuropathy (2,7%), rapidly progressive demyelinating polyneuropathy (10,8%), myopathy (10,8%)). 2 patients received IvIg course repeatedly during 2021-2022, both had PNS diseases. Neurological symptoms improved in 28 patients (75,6%) after the IvIg therapy. 7 patients (19,0%) had no improvement, but 2 patients (5,4%) deteriorated despite IvIg therapy. Only 2 patients experienced IvIg-related side effects – headache (1) and fever (1). . IvIg proved to be effective for both CNS and PNS pathology - improvement of neurological symptoms was observed in 75,6% of patients. Nevertheless, 5,4% of patients had progression of disease despite IvIg therapy. Our experience showed good safety profile of IvIg with therapy-related complications in only 5,4% of patients.
Period29 Mar 2023
Event titleRSU International Research Conference 2023: Knowledge for Use in Practice
Event typeConference
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational

Related content